Sex, gender, and health biotechnology: points to consider

<p>Abstract</p> <p>Background</p> <p>Reproductive technologies have been extensively debated in the literature. As well, feminist economists, environmentalists, and agriculturalists have generated substantial debate and literature on gender. However, the implications for women of health biotechnologies have received relatively less attention. Surprisingly, while gender based frameworks have been proposed in the context of public health policy, practice, health research, and epidemiological research, we could identify no systematic framework for gender analysis of health biotechnology in the developing world.</p> <p>Discussion</p> <p>We propose sex and gender considerations at five critical stages of health biotechnology research and development: priority setting; technology design; clinical trials; commercialization, and health services delivery.</p> <p>Summary</p> <p>Applying a systematic sex and gender framework to five key process stages of health biotechnology research and development could be a first step towards unlocking the opportunities of this promising science for women in the developing world.</p

Welcome kit for parliamentarians policy brief : assisted reproductive technologies (ARTs)

Low costs, easy access to otherwise highly regulated technologies and easy availability of surrogate mothers and gamete donors have made India a favoured destination for these procedures posing ethical, legal and social dilemmas, including the increasing commodification and commercialization of women's reproductive tissues. This policy brief highlights concerns with regard to the Draft Assisted Reproductive Technology (Regulation) Bill, to engage parliamentarians and policy makers towards a more effective and comprehensive legislation. There should be clear articulation of health risks borne by the users, especially women and surrogate mothers, and the children born through ARTs